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Abstract
The purpose of translational research is to test, in humans, novel therapeutic strategies developed
through experimentation. Translational research should be regarded as a two-way road: Bench to
Bedside and Bedside to Bench. However, Bedside to Bench efforts have regrettably been limited
because the scientific aspects are poorly understood by full time clinicians and the difficulty of
dealing with humans poorly appreciated by basic scientists. Translational research would be most
useful to the scientific community at large if journals would foster specific interest for the
publication of ex vivo human observation. The review process for such work should be assigned to
clinical scientists competent not only in the intricacies of molecular or cell biology but also intimate
with the reality of Internal Review Boards, ethics committees, Governmental Regulatory Agencies
and most importantly the humane aspects of dealing with sick individuals and their families. This
approach may focus both basic and clinical scientists and those struggling to fill the gap between
them on the effective treatment of diseases affecting women, men and children making translational
research more than an interesting concept.
Introduction
The purpose of translational research is to test, in humans,
novel therapeutic strategies developed through experi-
mentation. This concept is so popular that Bench to Bed-
side Awards were developed within the NIH to encourage
collaboration between clinicians and basic scientists
across institutes. But a more realistic approach would be
to encourage opportunities to pursue Bedside to Bench
research since our understanding of human disease is still
limited and pre-clinical models have shown a discourag-
ing propensity to fail when applied to humans. Transla-
tional research should be regarded as a two-way road:
Bench to Bedside and Bedside to Bench. However, Bed-
side to Bench efforts have regrettably been relegated to a
Cinderella role because the scientific aspects are poorly
understood by full time clinicians and the difficulty of
dealing with humans poorly appreciated by basic scien-
tists. In practice, Bedside to Bench information, though
conceptually valuable, is often frustrated by an unsympa-
thetic review process.
Specific hurdles
Indeed, the scientist attempting to dissect scientifically
human diseases as they evolve has to confront unique
challenges related with the genetic polymorphism of our
species, the extreme and evolving heterogeneity of some
diseases (such as cancer or viral disease) and often exter-
nal constraints posed by ethical and practical considera-
tions. Thus, some prefer to pre-fabricate animal models
resembling human diseases to enable the mathematical
prediction of a given treatment outcome by simplifying its
biology through standardization of the genetic makeup of
animals and diseases. These models, however, do not rep-
resent the basic essence of human diseases: they represent
attempts to put the bull's eye in the trajectory of the pro-
jectile rather than designing a weapon capable of hitting a
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moving target. "Clean" studies can be performed in
humans following Phase III and some Phase II trials
where clinical conditions are carefully designed and con-
sistently maintained. However, such trials do not repre-
sent the primary purpose of translational research: the
simple necessity to assess the effectiveness of a therapeutic
modality in a Phase III context suggests minimal if any
benefit.
The heart of translational research resides in Phase I trials
where novel treatments are tested for feasibility and toxic-
ity in preparation for a Phase II trial in which therapeutic
effectiveness is tested. In the wake of a potential "break-
through" in the lab, the Phase I trial offers great tempta-
tion to test what could be a pioneering therapeutic effect
and learn from the novel concepts derived from clinical
experience that could be shared with those bench scien-
tists who originally conceived the treatment. But, since,
unfortunately, minimal clinical benefit is usually seen in
the context of exploratory studies, enthusiasm fades and a
Phase II study does not materialize; attention turns to new
therapeutic modalities brought to the clinical shore from
a new Bench to Bedside wave.
How science fails us
Here is where the scientific community drops the ball.
Often scientists that designed new potential therapies
based on fundamental scientific breakthroughs are not
inclined to learn why things did not work as well in
humans as they did in the pre-clinical settings because
there is no room in prestige journals for negative results.
Indeed, the scientific community is not generally inter-
ested in negative results. In addition, difficulty in publish-
ing results derived from phase I studies is compounded by
the fact that often data are of compromised quality and
not of the pristine quality achievable in the pre-clinical
setting. Also, Phase I clinical studies in particular are char-
acterized by evolving treatment strategies such as dose
escalations and modifications dictated by regulatory agen-
cies or demanded by clinical realities. For example, the
patient population enrolled in phase I studies is primarily
constituted of individuals who failed standard therapy
and face terminal disease. In these individuals, therapies
often need modification according to acute need for palli-
ation and/or life saving procedures due to clinical emer-
gencies. Finally, Phase I studies are limited in patient
accrual and sample population. Yet, information derived
from these pilot studies may offer precious insight for the
rethinking of therapeutic strategies particularly when a
Phase II study will not take place due to the failure of a
Phase I study to meet expectations. Prestigious journals,
however, appear more fascinated with the modern
mythology of transgenic and knock-out mice than the
humble reality of human disease. Thus, new ideas and
related therapies based on genetically engineered results
of ever growing complexity are continuously published to
compensate for previous failures.
More effective collaboration
Translational research would be most useful to the scien-
tific community at large if journals would spare some pre-
cious space for ex vivo human observation or a specialized
journal would be envisioned. The review process for such
work should be assigned to clinical scientists competent
not only in the intricacies of molecular or cell biology but
also intimate with the reality of Internal Review Boards,
ethics committees, Governmental Regulatory Agencies
and most importantly the humane aspects of dealing with
animals who can talk and have a life outside of a cage.
This deeper approach may keep all of us honest by focus-
ing both basic and clinical scientists and those struggling
to fill the gap between them on the endgame: the effective
treatment of diseases affecting women, men and children.
The scientific process is meant, after all, to alleviate
human misery and this ultimate goal could be facilitated
by connecting basic scientists with the reality of human
disease and making translational research more than an
interesting concept.
A new journal
We are therefore, starting a new open access Journal
devoted to the appropriate peer review and rapid publica-
tion of results obtained through human investigation that
may be of benefit to the scientific community and vice
versa. The uniqueness of the journal will reside in the
selection of a specialized editorial board composed of
individuals with expertise in both the clinical as well as
the basic aspects of science. Hopefully, the Journal of
Translational Medicine will contribute to the advance-
ment of clinical care through sympathetic collaboration
between scientists and clinicians.